Company / Cash & Equivalents
Bicara Therapeutics Inc. Cash & Equivalents History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$489.7M
FY2024
5-year range
$230.4M / $489.7M
FY2023-FY2024
Trend
+112.5%
vs FY2023
Sector context
#43 of 207
Health Care
What the data says
Bicara Therapeutics Inc.'s cash & equivalents of $490M is higher than 79% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$490M in FY2024. Top quartile in the Health Care sector.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 207This company $489.7M Sector average $669.5M
▼
-26.9% below sector average
Key checks
Key Insights
- In FY2024, cash & equivalents increased 112.5% year-over-year.
- Ranks #43 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 11.58 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $489.7M | +112.5% |
| FY2023 | $230.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026